ID   B16-F1
AC   CVCL_0158
SY   B16/F1; B16 F1; B16F1
DR   BTO; BTO:0003853
DR   CLO; CLO_0001793
DR   CLO; CLO_0050764
DR   MCCL; MCC:0000050
DR   CLDB; cl337
DR   CLDB; cl338
DR   ATCC; CRL-6323
DR   BCRC; 60030
DR   BCRJ; 0045
DR   BioSample; SAMN11397654
DR   CCRID; 3111C0001CCC000365
DR   CCRID; 3142C0001000000039
DR   CCTCC; GDC0039
DR   CLS; 400122/p793_B16-F1
DR   ECACC; 92101203
DR   KCLB; 80007
DR   Lonza; 1278
DR   NCI-DTP; B16F1
DR   RCB; RCB2649
DR   TKG; TKG 0347
DR   TOKU-E; 581
DR   Wikidata; Q54752433
RX   PubMed=210294;
RX   PubMed=1109790;
RX   PubMed=6498800;
RX   PubMed=6539703;
RX   PubMed=11833741;
RX   PubMed=25277546;
RX   PubMed=31220119;
WW   http://www.cellresource.cn/fdetail.aspx?id=807
WW   http://www.cellresource.cn/fdetail.aspx?id=1554
CC   Characteristics: Obtained after from the pulmonary melanoma module of the 1st serial passage of the B16-F0 parent cell line in C57BL/6 mice.
CC   Characteristics: Has a low metastatic potential.
CC   Doubling time: 22 hours (PubMed=1109790).
CC   Omics: SNP array analysis.
CC   Breed/subspecies: C57BL/6.
ST   Source(s): PubMed=31220119
ST   Mouse STR 1-1: 17,18
ST   Mouse STR 1-2: 19,20
ST   Mouse STR 11-2: 16,17
ST   Mouse STR 12-1: 17,18
ST   Mouse STR 13-1: 17,18
ST   Mouse STR 15-3: 22.3,23.3
ST   Mouse STR 17-2: 15,16,17
ST   Mouse STR 18-3: 15,16
ST   Mouse STR 19-2: 13
ST   Mouse STR 2-1: 16
ST   Mouse STR 3-2: 14,15
ST   Mouse STR 4-2: 20.3,21.3
ST   Mouse STR 5-5: 16,20
ST   Mouse STR 6-4: 18,19
ST   Mouse STR 6-7: 15
ST   Mouse STR 7-1: 26.2
ST   Mouse STR 8-1: 16,17
ST   Mouse STR X-1: 28
DI   NCIt; C21790; Mouse melanoma
OX   NCBI_TaxID=10090; ! Mus musculus
HI   CVCL_0604 ! B16-F0
SX   Male
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-07-19; Version: 19
//
RX   PubMed=210294; DOI=10.1093/jnci/61.2.523;
RA   Niles R.M., Makarski J.S.;
RT   "Control of melanogenesis in mouse melanoma cells of varying
RT   metastatic potential.";
RL   J. Natl. Cancer Inst. 61:523-526(1978).
//
RX   PubMed=1109790;
RA   Fidler I.J.;
RT   "Biological behavior of malignant melanoma cells correlated to their
RT   survival in vivo.";
RL   Cancer Res. 35:218-224(1975).
//
RX   PubMed=6498800; DOI=10.1016/0304-3835(84)90080-6;
RA   Wosko T.J., Ferrara D.T., Sartori L.S.;
RT   "Histological comparison of the B16 melanoma and its F1 variant.";
RL   Cancer Lett. 24:57-63(1984).
//
RX   PubMed=6539703; DOI=10.1016/0277-5379(84)90015-4;
RA   Weinreb A., Travo P.;
RT   "Discrimination between human melanoma cell lines by fluorescence
RT   anisotropy.";
RL   Eur. J. Cancer Clin. Oncol. 20:673-677(1984).
//
RX   PubMed=11833741; DOI=10.1016/S0024-3205(01)01454-0;
RA   Nakamura K., Yoshikawa N., Yamaguchi Y., Kagota S., Shinozuka K.,
RA   Kunitomo M.;
RT   "Characterization of mouse melanoma cell lines by their mortal
RT   malignancy using an experimental metastatic model.";
RL   Life Sci. 70:791-798(2002).
//
RX   PubMed=25277546; DOI=10.1186/1471-2164-15-847;
RA   Didion J.P., Buus R.J., Naghashfar Z., Threadgill D.W.,
RA   Morse H.C. III, de Villena F.P.;
RT   "SNP array profiling of mouse cell lines identifies their strains of
RT   origin and reveals cross-contamination and widespread aneuploidy.";
RL   BMC Genomics 15:847-847(2014).
//
RX   PubMed=31220119; DOI=10.1371/journal.pone.0218412;
RA   Almeida J.L., Dakic A., Kindig K., Kone M., Letham D.L.D., Langdon S.,
RA   Peat R., Holding-Pillai J., Hall E.M., Ladd M., Shaffer M.D., Berg H.,
RA   Li J., Wigger G., Lund S., Steffen C.R., Fransway B.B., Geraghty B.,
RA   Natoli M., Bauer B., Gollin S.M., Lewis D.W., Reid Y.A.;
RT   "Interlaboratory study to validate a STR profiling method for
RT   intraspecies identification of mouse cell lines.";
RL   PLoS ONE 14:E0218412-E0218412(2019).
//